ClinicalTrials.gg
CompletedNCT03797326Updated May 4, 2026Results posted

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)

A Phase 2 interventional study of Pembrolizumab and Lenvatinib in Advanced Solid Tumors, Triple Negative Breast Cancer and Ovarian Cancer, sponsored by Merck Sharp & Dohme LLC. Completed at 88 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-04.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
611
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 49 studies testing pembrolizumab in Triple Negative Breast Neoplasms — 17 open to participants now, 27 under way, 4 of them phase 3. pembrolizumab · Triple Negative Breast Neoplasms.

Enrollment
8th of 49
611 · median 52
Started
2019
with 1 other
Phase 2
33 of 49
13 open now
Registered
25th of 49
by date
Lead sponsor
5 of 49
Merck Sharp & Dohme LLC

Among the 49 studies testing pembrolizumab in Triple Negative Breast Neoplasms, this one is the 8th largest by enrollment, is one of 2 that started in 2019, is one of 33 in phase 2, and was the 25th registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 445 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

17 of the 49 studies testing pembrolizumab in Triple Negative Breast Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About pembrolizumab

pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Triple Negative Breast Neoplasms studies recruiting now, 232 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies testing pembrolizumab in Triple Negative Breast Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to determine the safety and efficacy of combination therapy with pembrolizumab (MK-3475) and lenvatinib (E7080/MK-7902) in participants with triple negative breast cancer (TNBC), ovarian cancer, gastric cancer, colorectal cancer (CRC), glioblastoma (GBM), biliary tract cancers (BTC), or pancreatic cancer.

03

Conditions studied

  • Advanced Solid Tumors
  • Triple Negative Breast Cancer
  • Ovarian Cancer
  • Gastric Cancer
  • Colorectal Cancer
  • Glioblastoma
  • Biliary Tract Cancers
  • Pancreatic Cancer

Keywords

  • programmed cell death 1 (PD-1, PD1)
  • programmed cell death ligand 1 (PD-L1, PDL1)
  • programmed cell death ligand 2 (PD-L2, PDL2)
  • tyrosine kinase inhibitor (TKI)
  • multiple TKI
  • Vascular Endothelial Growth Factor Receptor (VEFG)
  • Fibroblast Growth Factor (FGF)
  • Platelet-Derived Growth Factor (PDGF)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a or cytologically-documented, advanced ( and/or unresectable) solid tumor that is incurable and for which prior standard systemic therapy has failed in one of the following cohorts: TNBC, Ovarian Cancer, Gastric Cancer, Colorectal Cancer, GBM, BTC (intrahepatic, extrahepatic cholangiocarcinoma and gall bladder cancer; excludes Ampulla of Vater), Pancreatic Cancer
  • Must have progressed on or since the last treatment
  • Has per 1.1 (RANO for the GBM cohort) as assessed by the local site investigator/radiology and confirmed by BICR
  • Has provided a evaluable sample or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated
  • Male participants agree to use approved during the treatment period for at least 7 days after the last dose of lenvatinib, or refrain from heterosexual intercourse during this period
  • Female participants are not pregnant or breastfeeding, and are not a woman of (WOCBP), OR are a WOCBP that agrees to use contraception during the treatment period (or 14 days prior to the initiation of study treatment for oral contraception) and for at least 120 days post pembrolizumab, or 30 days post lenvatinib, whichever occurs last
  • Has an (ECOG) performance status of 0 to 1 within 3 days of study treatment initiation
  • Has adequate organ function

For Triple Negative Breast Cancer Participants:

  • Has received one or 2
  • Has Lactate Dehydrogenase (LDH) \<2.0 x (ULN)
  • Has locally determined results for estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 tumor analyses

For Ovarian Cancer Participants:

- Has primary ovarian cancer and has received 3 prior lines of therapy.

For Gastric Cancer Participants:

- Has received 2 prior lines of therapy. Note: Gastric cancer will include participants with both gastric and gastroesophageal junction (GEJ) adenocarcinoma. Participants with squamous cell carcinoma histology are not eligible

For Colorectal Cancer Participants:

- Has received 2 prior lines of therapy

For GBM Participants:

  • Has failed initial systemic therapy for newly diagnosed GBM
  • Have the following time periods elapsed before the projected start of scheduled study treatment: 1) at least 3 weeks from prior surgical resection, 2) at least 1 week from stereotactic biopsy, 3) at least 6 months from completion of prior radiotherapy, 4) at least 4 weeks (or 5 half-lives, whichever is shorter) from any agent, 5) at least 4 weeks from cytotoxic therapy, 6) at least 6 weeks from antibodies, 7) at least 4 weeks (or 5 half-lives, whichever is shorter) from other antitumor therapies and 1 week for cancer vaccines
  • Be neurologically stable (e.g. without a progression of neurologic symptoms or requiring escalating doses of systemic therapy within last 2 weeks) and clinically stable
  • Has histologically confirmed World Health Organization (WHO) Grade IV GBM
  • Has locally determined result for O\^6-methylguanine-DNA methyltransferase (MGMT) analysis

For Biliary Tract Cancer Participants:

  • Has received 1 prior line of therapy
  • Score, Class A: well-compensated disease. Child-Pugh Score of 5-6

For Pancreatic Cancer Participants:

  • Has pathologically (histologically or cytologically) confirmed pancreatic ductal adenocarcinoma that is metastatic at enrollment
  • Has received one or 2 prior lines of therapy
  • Has received prior therapy with at least 1 (platinum-containing regimen or gemcitabine-containing regimen) but no more than 2 prior systemic therapies for unresectable or metastatic pancreatic cancer

Exclusion criteria

Exclusion Criteria:

  • Has gastrointestinal malabsorption or any other condition that might affect the absorption of lenvatinib
  • Has present or progressive accumulation of pleural, ascitic, or pericardial fluid requiring drainage or diuretic drugs within 2 weeks prior to enrollment (applies to all cohorts except the ovarian cancer cohort)
  • Has radiographic evidence of encasement or invasion of a major blood vessel or of intratumoral cavitation. Participants with portal vein invasion (Vp4), inferior vena cava, or cardiac involvement based on imaging in the BTC cohort are not eligible for enrollment
  • Has clinical significant hemoptysis or tumor bleeding within 2 weeks prior to the first dose of study treatment
  • Has significant cardiovascular impairment within 12 months of the first dose of study treatment, such as history of congestive heart failure greater than (NYHA) Class II, unstable angina, myocardial infarction or cerebrovascular accident (CVA), or cardiac arrhythmia associated with hemodynamic instability
  • Has a history of arterial thromboembolism within 12 months of start of study treatment
  • Has a known additional that is progressing or has required active treatment within the past 3 years.
  • Has a serious nonhealing wound, ulcer or bone fracture
  • Has had major surgery within 3 weeks prior to first dose of study interventions
  • Has biologic response modifiers therapy (e.g. granulocyte colony-stimulating factor) within 4 weeks before study entry
  • Has preexisting ≥Grade 3 gastrointestinal (GI) or non-gastrointestinal fistula
  • Has received prior therapy with lenvatinib, an , anti-PD-L1, or anti PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g. cytotoxic T-lymphocyte-associated protein 4 [CTLA-4], Tumor necrosis factor receptor superfamily, member 4 [OX 40], tumor necrosis factor receptor superfamily member 9 [CD137])
  • Has received prior systemic anti-cancer therapy including agents within 4 weeks prior to study treatment start
  • If participant received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment
  • Has received prior radiotherapy within 2 weeks of start of study treatment. Participants must have recovered from all radiation-related toxicities, not require , and not have had radiation pneumonitis. A 1-week is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-central nervous system (CNS) disease
  • Has received a within 30 days prior to the first dose of study treatment
  • Has known intolerance to lenvatinib (and/or any of the )
  • Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment
  • Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of therapy within 7 days prior the first dose of study treatment
  • Has known active and/or carcinomatous meningitis
  • Has tumors involving the brain stem
  • Has severe (≥Grade 3) to pembrolizumab and/or any of its excipients
  • Has an active disease that has required systemic treatment in past 2 years
  • Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis
  • Has an active infection requiring systemic therapy
  • Has a known history of (HIV) infection
  • Has a known history of or known active virus infection
  • Has a known history of active tuberculosis (TB; Bacillus tuberculosis)
  • Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study treatment
  • Has had an allogenic tissue/solid organ transplant (large organ transplants, stem-cell transplant requiring chronic immunosuppressant therapy necessary to prevent graft rejection)

For GBM Participants:

  • Has carcinomatous meningitis
  • Has recurrent tumor greater than 6 cm in maximum diameter
  • Has tumor primarily localized to the brainstem or spinal cord
  • Has presence of multifocal tumor, diffuse or extracranial disease
  • Has evidence of intratumoral or peritumoral hemorrhage on baseline magnetic resonance imaging (MRI) scan other than those that are grade ≤ 1 and either post-operative or stable on at least 2 consecutive MRI scans
  • Has received Optune® TTFields within 2 weeks of study intervention
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
611 participants (actual)

Study arms

  • Experimental
    Pembrolizumab + Lenvatinib (Arm 1)

    Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) plus lenvatinib 20 mg via oral capsule once a day (QD). Pembrolizumab will be administered for up to 35 cycles (up to 2 years). Lenvatinib will be administered until progressive disease or unacceptable toxicity (up to at least 2 years).

    Biological: Pembrolizumab · Drug: Lenvatinib

  • Experimental
    Lenvatinib Monotherapy (Arm 2)

    Participants receive lenvatinib 24 mg via oral capsule QD, to be administered until progressive disease or unacceptable toxicity (up to at least 2 years).

    Drug: Lenvatinib

Interventions

  • BiologicalPembrolizumab

    Administered as an IV infusion on Day 1 Q3W.

    Also known as: MK-3475, Keytruda®

  • Administered orally once a day during each 21-day cycle.

    Also known as: MK-7902, E7080, LENVIMA™

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Investigator Assessment

    ORR was defined as the percentage of participants who had a best overall response of either Complete Response (CR): Disappearance of all target lesions or Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions as assessed by RECIST 1.1. The percentage of participants who experienced a CR or PR as assessed by RECIST 1.1 by investigator assessment was presented. Per protocol, only data for Cohorts A and B were presented for this endpoint.

    Time frame: Up to approximately 66 months

  2. Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) or Response Assessment in Neuro-Oncology (RANO) Criteria (for Glioblastoma Multiforma [GBM] Only), by Blinded Independent Central Review (BICR)

    ORR was defined as the percentage of participants who had a best overall response of either Complete Response (CR): Disappearance of all target lesions or Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions as assessed by RECIST 1.1. For participants with GBM, response was assessed according to RANO criteria whereby ORR was defined as the percentage of participants who had a best overall response of either Complete response (CR): Disappearance of all target lesions or Partial response (PR): sum of products of diameters decreased by ≥50% from baseline value. The percentage of participants who experienced a CR or PR as assessed by RECIST 1.1 or RANO by BICR was presented. Per protocol, only data for Cohorts C, D1, D2, E, F, and G were presented for this endpoint.

    Time frame: Up to approximately 66 months

  3. Number of Participants With One or More Adverse Events (AEs)

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants with at least one or more AE is presented.

    Time frame: Up to approximately 66 months

  4. Number of Participants Who Discontinued From Study Treatment Due to an AE

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinued from study treatment due to an AE is presented.

    Time frame: Up to approximately 62 months

Secondary outcomes

  1. Disease Control Rate (DCR) Per RECIST 1.1 by Investigator Assessment

    DCR was defined per RECIST 1.1 as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) or Stable Disease (SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease \[PD: At least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD\]). Disease Control rate per RECIST 1.1 by investigator assessment is presented. Per protocol, only data for Cohorts A and B were presented for this endpoint.

    Time frame: Up to approximately 66 months

  2. Disease Control Rate (DCR) Per RECIST 1.1 or RANO Criteria (GBM Only) by BICR

    DCR was defined per RECIST 1.1 as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) or Stable Disease (SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease \[PD: At least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm\]). The appearance of one or more new lesions is also considered PD.\]). For participants with GBM, response was assessed according to RANO criteria whereby overall response was based on both radiographic response (CR: disappearance of all target lesions, PR: sum of products of diameters \[SPD\] decreased by ≥ 50% from baseline value and SD: SPD \<50% decreased from baseline, but \<25% increased from nadir) and clinical performance status with steroid dose information. The DCR as assessed by BICR is presented.

    Time frame: Up to approximately 66 months

  3. Duration of Response (DOR) Per RECIST 1.1 by Investigator Assessment

    For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR was defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. Duration of response per RECIST 1.1 by investigator assessment is presented. Per protocol, only data for Cohorts A and B were presented for this endpoint.

    Time frame: Up to approximately 66 months

  4. Duration of Response (DOR) Per RECIST 1.1 or RANO Criteria (GBM Only) by BICR

    For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR was defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. For participants with GBM, response will be assessed according to RANO criteria whereby overall RANO response is based on both radiographic response (CR: disappearance of all target lesions, PR: SPD decreased by ≥ 50% from baseline value) and clinical performance status with steroid dose information. DOR assessments were based on blinded central imaging review with confirmation.

    Time frame: Up to approximately 66 months

  5. Progression-Free Survival (PFS) Per RECIST 1.1 by Investigator Assessment

    PFS was defined as the time from date of study treatment to the first documented progressive disease (PD) based on RECIST 1.1, modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. The percentage of participants who experienced PFS per RECIST 1.1 by investigator assessment is presented. Per protocol, only data for Cohorts A and B were presented for this endpoint.

    Time frame: Up to approximately 66 months

  6. Progression-Free Survival (PFS) Per RECIST 1.1 or RANO Criteria (GBM Only) by BICR

    PFS was defined as the time from date of study treatment to the first documented progressive disease (PD) based on RECIST 1.1 (or RANO for GBM participants), modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. For participants with GBM, either radiological progression or clinical deterioration (not attributable to a nontumor-related cause) qualifies as PD. The percentage of participants who experienced PFS per RECIST 1.1 or RANO by BICR is presented. Per protocol, only data for Cohorts C, D1, D2, E, F, and G were presented for this endpoint.

    Time frame: Up to approximately 66 months

  7. Overall Survival (OS)

    OS was defined as the time from the date of study treatment to the date of death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. The OS for all participants is presented.

    Time frame: Up to approximately 66 months

  8. Area Under the Concentration Curve at Steady State (AUCss) of Lenvatinib

    Blood samples were collected at pre-specified timepoints to determine the AUCss in participants receiving Lenvatinib (Lenva) co-administered with Pembrolizumab (Pembro). AUCss was defined as a measure of drug exposure that was calculated as the product of plasma drug concentration and time after drug administration at steady state. AUCss determined by blood samples collected pre-dose and at designated timepoints post-dose are presented. Noncompartmental analysis was used to calculate AUC0ss for each participant. Mean and standard deviation of AUCss were calculated for each cohort. As specified in the protocol, pharmacokinetic analysis was not planned or conducted in Cohorts D2 and G.

    Time frame: Cycle 1 Day 1: 0.5-4 hours and 6-10 hours post-dose; Cycle 1 Day 15: pre-dose and 2-12 hours post-dose; Cycle 2 Day 1: pre-dose, 0.5-4 hours, and 6-10 hours post-dose (up to approximately 23 days). Each cycle is 21 days.

07

Results

Posted Nov 17, 2025

Participant flow

This study was conducted at 85 centers in 17 countries.

Participant flow — Overall Study
MilestoneCohort A: Triple Negative Breast Cancer (Lenva + Pembro)Cohort B: Ovarian Cancer (Lenva + Pembro)Cohort C: Gastric Cancer (Lenva + Pembro)Cohort D1: Colorectal Cancer (Lenva + Pembro)Cohort D2: Colorectal Cancer (Lenva)Cohort E: Glioblastoma Multiforma (Lenva + Pembro)Cohort F: Biliary Tract Cancer (Lenva + Pembro)Cohort G: Pancreatic Cancer (Lenva + Pembro)
Started313110210732102103103
Treated31319910530101102103
Completed00000000
Not completed313110210732102103103
Withdrew: Lost to follow-up10010000
Withdrew: Withdrawal by subject00130223
Withdrew: Sponsor decision33360332
Withdrew: Death2728959530969798
Withdrew: Enrolled in error00322110

Outcome measures

SecondaryDisease Control Rate (DCR) Per RECIST 1.1 by Investigator Assessment

DCR was defined per RECIST 1.1 as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) or Stable Disease (SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease \[PD: At least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD\]). Disease Control rate per RECIST 1.1 by investigator assessment is presented. Per protocol, only data for Cohorts A and B were presented for this endpoint.

Time frame:
Up to approximately 66 months
Reported as:
Number · Percentage of Participants
Disease Control Rate (DCR) Per RECIST 1.1 by Investigator Assessment
Percentage of ParticipantsCohort A: Triple Negative Breast Cancer (Lenva + Pembro)Cohort B: Ovarian Cancer (Lenva + Pembro)
Disease Control Rate (DCR) Per RECIST 1.1 by Investigator Assessment51.6 (33.1 to 69.8)77.4 (58.9 to 90.4)
SecondaryDisease Control Rate (DCR) Per RECIST 1.1 or RANO Criteria (GBM Only) by BICR

DCR was defined per RECIST 1.1 as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) or Stable Disease (SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease \[PD: At least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm\]). The appearance of one or more new lesions is also considered PD.\]). For participants with GBM, response was assessed according to RANO criteria whereby overall response was based on both radiographic response (CR: disappearance of all target lesions, PR: sum of products of diameters \[SPD\] decreased by ≥ 50% from baseline value and SD: SPD \<50% decreased from baseline, but \<25% increased from nadir) and clinical performance status with steroid dose information. The DCR as assessed by BICR is presented.

Time frame:
Up to approximately 66 months
Reported as:
Number · Percentage of Participants
Disease Control Rate (DCR) Per RECIST 1.1 or RANO Criteria (GBM Only) by BICR
Percentage of ParticipantsCohort C: Gastric Cancer (Lenva + Pembro)Cohort D1: Colorectal Cancer (Lenva + Pembro)Cohort D2: Colorectal Cancer (Lenva)Cohort E: Glioblastoma Multiforma (Lenva + Pembro)Cohort F: Biliary Tract Cancer (Lenva + Pembro)Cohort G: Pancreatic Cancer (Lenva + Pembro)
Disease Control Rate (DCR) Per RECIST 1.1 or RANO Criteria (GBM Only) by BICR53.5 (43.2 to 63.6)52.4 (42.4 to 62.2)56.7 (37.4 to 74.5)57.4 (47.2 to 67.2)64.7 (54.6 to 73.9)37.9 (28.5 to 48.0)
SecondaryDuration of Response (DOR) Per RECIST 1.1 by Investigator Assessment

For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR was defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. Duration of response per RECIST 1.1 by investigator assessment is presented. Per protocol, only data for Cohorts A and B were presented for this endpoint.

Time frame:
Up to approximately 66 months
Reported as:
Median · Months
Duration of Response (DOR) Per RECIST 1.1 by Investigator Assessment
MonthsCohort A: Triple Negative Breast Cancer (Lenva + Pembro)Cohort B: Ovarian Cancer (Lenva + Pembro)
Duration of Response (DOR) Per RECIST 1.1 by Investigator Assessment22.9 (4.2 to NA)15.3 (6.4 to NA)
SecondaryDuration of Response (DOR) Per RECIST 1.1 or RANO Criteria (GBM Only) by BICR

For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR was defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. For participants with GBM, response will be assessed according to RANO criteria whereby overall RANO response is based on both radiographic response (CR: disappearance of all target lesions, PR: SPD decreased by ≥ 50% from baseline value) and clinical performance status with steroid dose information. DOR assessments were based on blinded central imaging review with confirmation.

Time frame:
Up to approximately 66 months
Reported as:
Median · Months
Duration of Response (DOR) Per RECIST 1.1 or RANO Criteria (GBM Only) by BICR
MonthsCohort C: Gastric Cancer (Lenva + Pembro)Cohort D1: Colorectal Cancer (Lenva + Pembro)Cohort D2: Colorectal Cancer (Lenva)Cohort E: Glioblastoma Multiforma (Lenva + Pembro)Cohort F: Biliary Tract Cancer (Lenva + Pembro)Cohort G: Pancreatic Cancer (Lenva + Pembro)
Duration of Response (DOR) Per RECIST 1.1 or RANO Criteria (GBM Only) by BICR8.3 (4.2 to NA)8.3 (4.2 to 18.5)NA (NA to NA)4.6 (3.2 to 15.6)6.2 (4.2 to 7.1)5.8 (2.7 to NA)
SecondaryProgression-Free Survival (PFS) Per RECIST 1.1 by Investigator Assessment

PFS was defined as the time from date of study treatment to the first documented progressive disease (PD) based on RECIST 1.1, modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. The percentage of participants who experienced PFS per RECIST 1.1 by investigator assessment is presented. Per protocol, only data for Cohorts A and B were presented for this endpoint.

Time frame:
Up to approximately 66 months
Reported as:
Median · Months
Progression-Free Survival (PFS) Per RECIST 1.1 by Investigator Assessment
MonthsCohort A: Triple Negative Breast Cancer (Lenva + Pembro)Cohort B: Ovarian Cancer (Lenva + Pembro)
Progression-Free Survival (PFS) Per RECIST 1.1 by Investigator Assessment4.2 (1.7 to 6.3)6.1 (4.1 to 9.4)
SecondaryProgression-Free Survival (PFS) Per RECIST 1.1 or RANO Criteria (GBM Only) by BICR

PFS was defined as the time from date of study treatment to the first documented progressive disease (PD) based on RECIST 1.1 (or RANO for GBM participants), modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. For participants with GBM, either radiological progression or clinical deterioration (not attributable to a nontumor-related cause) qualifies as PD. The percentage of participants who experienced PFS per RECIST 1.1 or RANO by BICR is presented. Per protocol, only data for Cohorts C, D1, D2, E, F, and G were presented for this endpoint.

Time frame:
Up to approximately 66 months
Reported as:
Median · Months
Progression-Free Survival (PFS) Per RECIST 1.1 or RANO Criteria (GBM Only) by BICR
MonthsCohort C: Gastric Cancer (Lenva + Pembro)Cohort D1: Colorectal Cancer (Lenva + Pembro)Cohort D2: Colorectal Cancer (Lenva)Cohort E: Glioblastoma Multiforma (Lenva + Pembro)Cohort F: Biliary Tract Cancer (Lenva + Pembro)Cohort G: Pancreatic Cancer (Lenva + Pembro)
Progression-Free Survival (PFS) Per RECIST 1.1 or RANO Criteria (GBM Only) by BICR3.5 (2.3 to 4.1)3.4 (2.1 to 4.1)3.4 (2.1 to 4.8)3.0 (2.8 to 4.1)4.1 (3.6 to 5.9)2.1 (2.1 to 3.1)
SecondaryOverall Survival (OS)

OS was defined as the time from the date of study treatment to the date of death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. The OS for all participants is presented.

Time frame:
Up to approximately 66 months
Reported as:
Median · Months
Overall Survival (OS)
MonthsCohort A: Triple Negative Breast Cancer (Lenva + Pembro)Cohort B: Ovarian Cancer (Lenva + Pembro)Cohort C: Gastric Cancer (Lenva + Pembro)Cohort D1: Colorectal Cancer (Lenva + Pembro)Cohort D2: Colorectal Cancer (Lenva)Cohort E: Glioblastoma Multiforma (Lenva + Pembro)Cohort F: Biliary Tract Cancer (Lenva + Pembro)Cohort G: Pancreatic Cancer (Lenva + Pembro)
Overall Survival (OS)11.4 (4.1 to 21.7)21.3 (11.7 to 32.3)4.7 (3.8 to 6.1)8.7 (7.0 to 10.0)7.9 (5.6 to 14.9)8.6 (7.4 to 10.8)7.9 (5.6 to 9.5)4.3 (3.8 to 5.4)
SecondaryArea Under the Concentration Curve at Steady State (AUCss) of Lenvatinib

Blood samples were collected at pre-specified timepoints to determine the AUCss in participants receiving Lenvatinib (Lenva) co-administered with Pembrolizumab (Pembro). AUCss was defined as a measure of drug exposure that was calculated as the product of plasma drug concentration and time after drug administration at steady state. AUCss determined by blood samples collected pre-dose and at designated timepoints post-dose are presented. Noncompartmental analysis was used to calculate AUC0ss for each participant. Mean and standard deviation of AUCss were calculated for each cohort. As specified in the protocol, pharmacokinetic analysis was not planned or conducted in Cohorts D2 and G.

Time frame:
Cycle 1 Day 1: 0.5-4 hours and 6-10 hours post-dose; Cycle 1 Day 15: pre-dose and 2-12 hours post-dose; Cycle 2 Day 1: pre-dose, 0.5-4 hours, and 6-10 hours post-dose (up to approximately 23 days). Each cycle is 21 days.
Reported as:
Mean · ng*hr/mL
Area Under the Concentration Curve at Steady State (AUCss) of Lenvatinib
ng*hr/mLCohort A: Triple Negative Breast Cancer (Lenva + Pembro)Cohort B: Ovarian Cancer (Lenva + Pembro)Cohort C: Gastric Cancer (Lenva + Pembro)Cohort D1: Colorectal Cancer (Lenva + Pembro)Cohort E: Glioblastoma Multiforma (Lenva + Pembro)Cohort F: Biliary Tract Cancer (Lenva + Pembro)
Area Under the Concentration Curve at Steady State (AUCss) of Lenvatinib3253 ± 10293145 ± 9842392 ± 8032994 ± 11432617 ± 8042886 ± 838
PrimaryObjective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Investigator Assessment

ORR was defined as the percentage of participants who had a best overall response of either Complete Response (CR): Disappearance of all target lesions or Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions as assessed by RECIST 1.1. The percentage of participants who experienced a CR or PR as assessed by RECIST 1.1 by investigator assessment was presented. Per protocol, only data for Cohorts A and B were presented for this endpoint.

Time frame:
Up to approximately 66 months
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Investigator Assessment
Percentage of ParticipantsCohort A: Triple Negative Breast Cancer (Lenva + Pembro)Cohort B: Ovarian Cancer (Lenva + Pembro)
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Investigator Assessment22.6 (9.6 to 41.1)25.8 (11.9 to 44.6)
PrimaryObjective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) or Response Assessment in Neuro-Oncology (RANO) Criteria (for Glioblastoma Multiforma [GBM] Only), by Blinded Independent Central Review (BICR)

ORR was defined as the percentage of participants who had a best overall response of either Complete Response (CR): Disappearance of all target lesions or Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions as assessed by RECIST 1.1. For participants with GBM, response was assessed according to RANO criteria whereby ORR was defined as the percentage of participants who had a best overall response of either Complete response (CR): Disappearance of all target lesions or Partial response (PR): sum of products of diameters decreased by ≥50% from baseline value. The percentage of participants who experienced a CR or PR as assessed by RECIST 1.1 or RANO by BICR was presented. Per protocol, only data for Cohorts C, D1, D2, E, F, and G were presented for this endpoint.

Time frame:
Up to approximately 66 months
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) or Response Assessment in Neuro-Oncology (RANO) Criteria (for Glioblastoma Multiforma [GBM] Only), by Blinded Independent Central Review (BICR)
Percentage of ParticipantsCohort C: Gastric Cancer (Lenva + Pembro)Cohort D1: Colorectal Cancer (Lenva + Pembro)Cohort D2: Colorectal Cancer (Lenva)Cohort E: Glioblastoma Multiforma (Lenva + Pembro)Cohort F: Biliary Tract Cancer (Lenva + Pembro)Cohort G: Pancreatic Cancer (Lenva + Pembro)
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) or Response Assessment in Neuro-Oncology (RANO) Criteria (for Glioblastoma Multiforma [GBM] Only), by Blinded Independent Central Review (BICR)15.2 (8.7 to 23.8)14.3 (8.2 to 22.5)6.7 (0.8 to 22.1)21.8 (14.2 to 31.1)17.6 (10.8 to 26.4)7.8 (3.4 to 14.7)
PrimaryNumber of Participants With One or More Adverse Events (AEs)

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants with at least one or more AE is presented.

Time frame:
Up to approximately 66 months
Reported as:
Count of participants · Participants
Number of Participants With One or More Adverse Events (AEs)
ParticipantsCohort A: Triple Negative Breast Cancer (Lenva + Pembro)Cohort B: Ovarian Cancer (Lenva + Pembro)Cohort C: Gastric Cancer (Lenva + Pembro)Cohort D1: Colorectal Cancer (Lenva + Pembro)Cohort D2: Colorectal Cancer (Lenva)Cohort E: Glioblastoma Multiforma (Lenva + Pembro)Cohort F: Biliary Tract Cancer (Lenva + Pembro)Cohort G: Pancreatic Cancer (Lenva + Pembro)
Number of Participants With One or More Adverse Events (AEs)31319710430101102103
PrimaryNumber of Participants Who Discontinued From Study Treatment Due to an AE

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinued from study treatment due to an AE is presented.

Time frame:
Up to approximately 62 months
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued From Study Treatment Due to an AE
ParticipantsCohort A: Triple Negative Breast Cancer (Lenva + Pembro)Cohort B: Ovarian Cancer (Lenva + Pembro)Cohort C: Gastric Cancer (Lenva + Pembro)Cohort D1: Colorectal Cancer (Lenva + Pembro)Cohort D2: Colorectal Cancer (Lenva)Cohort E: Glioblastoma Multiforma (Lenva + Pembro)Cohort F: Biliary Tract Cancer (Lenva + Pembro)Cohort G: Pancreatic Cancer (Lenva + Pembro)
Number of Participants Who Discontinued From Study Treatment Due to an AE51123194112019

Adverse events

Collected over Up to approximately 66 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort A: Triple Negative Breast Cancer (Lenva + Pembro)27/31 (87.1%)16/31 (51.6%)30/31 (96.8%)
Cohort B: Ovarian Cancer (Lenva + Pembro)28/31 (90.3%)19/31 (61.3%)31/31 (100%)
Cohort C: Gastric Cancer (Lenva + Pembro)97/102 (95.1%)57/99 (57.6%)95/99 (96%)
Cohort D1: Colorectal Cancer (Lenva + Pembro)97/107 (90.7%)55/105 (52.4%)103/105 (98.1%)
Cohort D2: Colorectal Cancer (Lenva)30/32 (93.8%)12/30 (40%)29/30 (96.7%)
Cohort E: Glioblastoma Multiforma (Lenva + Pembro)99/102 (97.1%)30/101 (29.7%)98/101 (97%)
Cohort F: Biliary Tract Cancer (Lenva + Pembro)98/103 (95.1%)62/102 (60.8%)100/102 (98%)
Cohort G: Pancreatic Cancer (Lenva + Pembro)101/103 (98.1%)49/103 (47.6%)101/103 (98.1%)
Most frequent serious events
Showing 10 of 223
Most frequent serious events
EventCohort A: Triple Negative Breast Cancer (Lenva + Pembro)Cohort B: Ovarian Cancer (Lenva + Pembro)Cohort C: Gastric Cancer (Lenva + Pembro)Cohort D1: Colorectal Cancer (Lenva + Pembro)Cohort D2: Colorectal Cancer (Lenva)Cohort E: Glioblastoma Multiforma (Lenva + Pembro)Cohort F: Biliary Tract Cancer (Lenva + Pembro)Cohort G: Pancreatic Cancer (Lenva + Pembro)
Intestinal obstructionGastrointestinal disorders0/313/311/993/1050/300/1010/1020/103
PyrexiaGeneral disorders0/312/311/992/1050/304/1017/1021/103
DiarrhoeaGastrointestinal disorders1/312/313/993/1052/300/1012/1020/103
HyperbilirubinaemiaHepatobiliary disorders0/310/311/990/1052/300/1010/1020/103
VomitingGastrointestinal disorders0/312/312/991/1050/301/1012/1021/103
CholecystitisHepatobiliary disorders0/312/310/990/1051/300/1011/1020/103
PneumoniaInfections and infestations1/312/312/991/1050/301/1012/1021/103
Urinary tract infectionInfections and infestations0/312/310/993/1050/301/1010/1021/103
HyponatraemiaMetabolism and nutrition disorders1/312/310/991/1050/300/1012/1020/103
HeadacheNervous system disorders0/312/310/990/1050/300/1010/1020/103
Most frequent other events
Showing 10 of 107
Most frequent other events
EventCohort A: Triple Negative Breast Cancer (Lenva + Pembro)Cohort B: Ovarian Cancer (Lenva + Pembro)Cohort C: Gastric Cancer (Lenva + Pembro)Cohort D1: Colorectal Cancer (Lenva + Pembro)Cohort D2: Colorectal Cancer (Lenva)Cohort E: Glioblastoma Multiforma (Lenva + Pembro)Cohort F: Biliary Tract Cancer (Lenva + Pembro)Cohort G: Pancreatic Cancer (Lenva + Pembro)
HypertensionVascular disorders16/3121/3137/9959/10517/3051/10158/10255/103
DiarrhoeaGastrointestinal disorders14/3119/3130/9947/10516/3026/10142/10225/103
NauseaGastrointestinal disorders13/3115/3131/9934/1055/3019/10137/10237/103
Decreased appetiteMetabolism and nutrition disorders9/3115/3130/9946/1056/3019/10137/10233/103
HypothyroidismEndocrine disorders14/3114/3125/9946/10512/3028/10134/10228/103
FatigueGeneral disorders13/3114/3121/9941/1059/3020/10140/10231/103
VomitingGastrointestinal disorders10/3113/3115/9926/1058/3013/10120/10219/103
ProteinuriaRenal and urinary disorders6/3113/3112/9939/10511/3012/10123/10222/103
DysphoniaRespiratory, thoracic and mediastinal disorders5/313/3120/9921/10512/3011/10131/10217/103
Blood alkaline phosphatase increasedInvestigations2/316/3114/9913/10511/304/10114/1029/103

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Cohort A: Triple Negative Breast Cancer (Lenva + Pembro)Cohort B: Ovarian Cancer (Lenva + Pembro)Cohort C: Gastric Cancer (Lenva + Pembro)Cohort D1: Colorectal Cancer (Lenva + Pembro)Cohort D2: Colorectal Cancer (Lenva)Cohort E: Glioblastoma Multiforma (Lenva + Pembro)Cohort F: Biliary Tract Cancer (Lenva + Pembro)Cohort G: Pancreatic Cancer (Lenva + Pembro)Total
<=18 years000000000
Between 18 and 65 years2518687125835256398
>=65 years61334367195147213
Sex: Female, Male
Sex: Female, Male(Participants)Cohort A: Triple Negative Breast Cancer (Lenva + Pembro)Cohort B: Ovarian Cancer (Lenva + Pembro)Cohort C: Gastric Cancer (Lenva + Pembro)Cohort D1: Colorectal Cancer (Lenva + Pembro)Cohort D2: Colorectal Cancer (Lenva)Cohort E: Glioblastoma Multiforma (Lenva + Pembro)Cohort F: Biliary Tract Cancer (Lenva + Pembro)Cohort G: Pancreatic Cancer (Lenva + Pembro)Total
Female3131303214385342271
Male00727518645061340
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort A: Triple Negative Breast Cancer (Lenva + Pembro)Cohort B: Ovarian Cancer (Lenva + Pembro)Cohort C: Gastric Cancer (Lenva + Pembro)Cohort D1: Colorectal Cancer (Lenva + Pembro)Cohort D2: Colorectal Cancer (Lenva)Cohort E: Glioblastoma Multiforma (Lenva + Pembro)Cohort F: Biliary Tract Cancer (Lenva + Pembro)Cohort G: Pancreatic Cancer (Lenva + Pembro)Total
Hispanic or Latino62171991391691
Not Hispanic or Latino1923647723737686441
Unknown or Not Reported66211101618179
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort A: Triple Negative Breast Cancer (Lenva + Pembro)Cohort B: Ovarian Cancer (Lenva + Pembro)Cohort C: Gastric Cancer (Lenva + Pembro)Cohort D1: Colorectal Cancer (Lenva + Pembro)Cohort D2: Colorectal Cancer (Lenva)Cohort E: Glioblastoma Multiforma (Lenva + Pembro)Cohort F: Biliary Tract Cancer (Lenva + Pembro)Cohort G: Pancreatic Cancer (Lenva + Pembro)Total
American Indian or Alaska Native000000000
Asian54111721718882
Native Hawaiian or Other Pacific Islander000001001
Black or African American0024201211
White2223707125727190444
More than one race0024310313
Unknown or Not Reported44171101113060
08

Study locations

88 sites
  • City of Hope ( Site 0002)
    Duarte, California 91010, United States
  • Cedars Sinai Medical Center ( Site 0003)
    Los Angeles, California 90048, United States
  • University of California Davis Comprehensive Cancer Center ( Site 0005)
    Sacramento, California 95817, United States
  • University of Colorado, Anschutz Cancer Pavilion ( Site 0007)
    Aurora, Colorado 80045, United States
  • University of Florida-Health Cancer Center-Orlando ( Site 0015)
    Orlando, Florida 32806, United States
  • Rutgers Cancer Institute of New Jersey ( Site 0009)
    New Brunswick, New Jersey 08901, United States
  • Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 0023)
    New York, New York 10016, United States
  • Sanford Fargo Medical Center ( Site 0059)
    Fargo, North Dakota 58102, United States
  • Lehigh Valley Hospital- Cedar Crest ( Site 0047)
    Allentown, Pennsylvania 18103, United States
  • Sanford Cancer Center ( Site 0058)
    Sioux Falls, South Dakota 57104, United States
  • West Cancer Center - East Campus ( Site 0018)
    Germantown, Tennessee 38138, United States
  • Mary Crowley Cancer Research Centers - Medical City Hospital ( Site 0049)
    Dallas, Texas 75230, United States
  • Swedish Medical Center ( Site 0021)
    Seattle, Washington 98104, United States
  • University of Wisconsin Carbone Cancer Center ( Site 0017)
    Madison, Wisconsin 53792-0001, United States
  • Fundacion Favaloro para la Docencia e Investigacion Medica ( Site 2106)
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1078AAI, Argentina
  • Hospital Aleman ( Site 2100)
    Buenos Aires, Buenos Aires F.D. 1118, Argentina
  • Hospital Britanico de Buenos Aires ( Site 2109)
    Ciudad de Buenos Aires, Buenos Aires F.D. C1280AEB, Argentina
  • Instituto de Oncologia de Rosario ( Site 2105)
    Rosario, Santa Fe Province S2000KZE, Argentina
  • CEMIC ( Site 2104)
    Buenos Aires, C1431FWO, Argentina
  • IDIM Instituto de Diagnostico e Investigaciones Metabolicas ( Site 2101)
    Caba, C1012AAR, Argentina
  • Royal Brisbane and Women s Hospital ( Site 0901)
    Herston, Queensland 4029, Australia
  • Alfred Health ( Site 0902)
    Melbourne, Victoria 3004, Australia
  • Sir Charles Gairdner Hospital ( Site 0903)
    Nedlands, Western Australia 6009, Australia
  • BC Cancer - Abbotsford ( Site 0200)
    Abbotsford British Columbia, British Columbia V2S 0C2, Canada
  • CancerCare Manitoba ( Site 0201)
    Winnipeg, Manitoba R3E 0V9, Canada
  • Hamilton Health Sciences-Juravinski Cancer Centre ( Site 0208)
    Hamilton, Ontario L8V 4X2, Canada
  • Sunnybrook Research Institute ( Site 0207)
    Toronto, Ontario M4N 3M5, Canada
  • Princess Margaret Cancer Centre ( Site 0202)
    Toronto, Ontario M5G 2M9, Canada
  • Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0210)
    Montreal, Quebec H2X 3E4, Canada
  • CHU de Quebec Universite de Laval ( Site 0206)
    Québec, Quebec G1R 2J6, Canada
  • Centro Investigación del Cáncer James Lind ( Site 1203)
    Temuco, Araucania 4780000, Chile
  • Fundacion Arturo Lopez Perez ( Site 1201)
    Santiago, Region M. de Santiago 7500921, Chile
  • Pontificia Universidad Catolica de Chile ( Site 1202)
    Santiago, Region M. de Santiago 8330024, Chile
  • Hospital Clinico Universidad de Chile ( Site 1200)
    Santiago, Region M. de Santiago 8380456, Chile
  • Fundacion Colombiana de Cancerologia Clinica Vida ( Site 1105)
    Medellín, Antioquia 050030, Colombia
  • Instituto Nacional de Cancerologia E.S.E ( Site 1102)
    Bogotá, Bogota D.C. 110321, Colombia
  • Oncologos del Occidente S.A. ( Site 1106)
    Pereira, Risaralda Department 660001, Colombia
  • Fundacion Valle del Lili ( Site 1101)
    Cali, Valle del Cauca Department 760032, Colombia
  • Centre Antoine Lacassagne ( Site 0404)
    Nice, Alpes-Maritimes 06189, France
  • Centre Leon Berard ( Site 0405)
    Lyon, Auvergne 69373, France
  • Institut Claudius Regaud IUCT Oncopole ( Site 0403)
    Toulouse, Haute-Garonne 31059, France
  • Centre Oscar Lambret ( Site 0401)
    Lille, Nord 59000, France
  • Institut de Cancerologie de l Ouest Centre Rene Gauducheau ( Site 0402)
    Saint-Herblain, Val-de-Marne 44805, France
  • Institut Gustave Roussy ( Site 0400)
    Villejuif, Val-de-Marne 94800, France
  • Robert Bosch GmbH ( Site 0307)
    Stuttgart, Baden-Wurttemberg 70376, Germany
  • Universitaetsklinikum Regensburg ( Site 0304)
    Regensburg, Bavaria 93053, Germany
  • Universitaetsklinikum Frankfurt ( Site 0306)
    Frankfurt am Main, Hesse 60528, Germany
  • HELIOS Dr. Horst Schmidt Kliniken Wiesbaden ( Site 0301)
    Wiesbaden, Hesse 65199, Germany
  • SRH Wald-Klinikum Gera GmbH ( Site 0309)
    Gera, Thuringia 07548, Germany
  • Universitaetsklinikum Jena ( Site 0302)
    Jena, Thuringia 07740, Germany
  • Soroka Medical Center ( Site 0601)
    Beersheba, 8457108, Israel
  • Rambam Medical Center ( Site 0602)
    Haifa, 3109601, Israel
  • Hadassah Ein Kerem Medical Center ( Site 0604)
    Jerusalem, 9112001, Israel
  • Chaim Sheba Medical Center ( Site 0600)
    Ramat Gan, 5262000, Israel
  • Sourasky Medical Center ( Site 0603)
    Tel Aviv, 6423906, Israel
  • Istituto Clinico Humanitas Research Hospital ( Site 1402)
    Rozzano, Milano, Italy
  • Policlinico Le Scotte - A.O. Senese ( Site 1401)
    Siena, Tuscany 53100, Italy
  • Istituto Nazionale Tumori Fondazione Pascale ( Site 1400)
    Naples, 80131, Italy
  • Fondazione Policlinico Universitario A. Gemelli ( Site 1403)
    Roma, 00168, Italy
  • Arkhangelsk Clinical Oncological Dispensary ( Site 1600)
    Arkhangelsk, Arkhangelskaya oblast 163045, Russia
  • Russian Oncological Research Center n.a. N.N. Blokhin ( Site 1604)
    Moscow, Moscow 115478, Russia
  • Leningrad Regional Oncology Center ( Site 1609)
    Saint Petersburg, Sankt-Peterburg 188663, Russia
  • Scientific Research Oncology Institute n.a. N.N.Petrov ( Site 1610)
    Saint Petersburg, Sankt-Peterburg 197758, Russia
  • City Clinical Oncology Center ( Site 1608)
    Saint Petersburg, Sankt-Peterburg 198255, Russia
  • Republican Clinical Oncology Dispensary of Tatarstan MoH ( Site 1603)
    Kazan', Tatarstan, Respublika 420029, Russia
  • Asan Medical Center ( Site 1002)
    Songpagu, Seoul 05505, South Korea
  • Seoul National University Hospital ( Site 1000)
    Seoul, 03080, South Korea
  • Severance Hospital Yonsei University Health System ( Site 1001)
    Seoul, 03722, South Korea
  • Hospital Clinic i Provincial ( Site 0703)
    Barcelona, 08036, Spain
  • Hospital Universitario Gregorio Maranon ( Site 0701)
    Madrid, 28009, Spain
  • Clinica Universitaria de Navarra ( Site 0704)
    Madrid, 28027, Spain
  • Hospital Ramon y Cajal ( Site 0702)
    Madrid, 28034, Spain
  • Inselspital Universitaetsspital Bern ( Site 1705)
    Bern, Canton of Bern 3010, Switzerland
  • Kantonsspital St. Gallen ( Site 1702)
    Sankt Gallen, Canton of St. Gallen 9007, Switzerland
  • Ospedale Regionale di Bellinzona e Valli ( Site 1703)
    Bellinzona, Canton Ticino 6500, Switzerland
  • Kantonsspital Graubuenden ( Site 1704)
    Chur, Kanton Graubünden 7000, Switzerland
  • Hopitaux Universitaires de Geneve HUG ( Site 1701)
    Geneva, 1211, Switzerland
  • Universitaetsspital Zurich ( Site 1700)
    Zurich, 8091, Switzerland
  • National Cheng Kung University Hospital ( Site 3003)
    Tainan, 704, Taiwan
  • National Taiwan University Hospital ( Site 3000)
    Taipei, 10002, Taiwan
  • Chulalongkorn University ( Site 5001)
    Bangkok, Bangkok 10330, Thailand
  • Ramathibodi Hospital. ( Site 5002)
    Bangkok, Bangkok 10400, Thailand
  • Siriraj Hospital ( Site 5003)
    Bangkok, Bangkok 10700, Thailand
  • Cambridge University Hospitals NHS Trust ( Site 0803)
    Cambridge, Cambridgeshire CB2 0QQ, United Kingdom
  • Leicester Royal Infirmary. Univ. Hosp. of Leicester NHS Trust ( Site 0804)
    Leicester, Leicestershire LE1 5WW, United Kingdom
  • Guy's Hospital ( Site 0806)
    London, London, City of SE1 9RT, United Kingdom
  • Royal Marsden Hospital (Sutton) ( Site 0800)
    London, Surrey SM3 5PT, United Kingdom
  • Christie NHS Foundation Trust ( Site 0805)
    Manchester, M20 4BX, United Kingdom
09

References and documents

Publications

  • Gonzalez-Martin A, Chung HC, Saada-Bouzid E, Yanez E, Senellart H, Cassier PA, Basu B, Corr BR, Girda E, Dutcus C, Okpara CE, Ghori R, Jin F, Groisberg R, Lwin Z. Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study. Gynecol Oncol. 2024 Jul;186:182-190. doi: 10.1016/j.ygyno.2024.04.011. Epub 2024 May 7. PubMed 38718741 ↗
  • Chung HC, Saada-Bouzid E, Longo F, Yanez E, Im SA, Castanon E, Desautels DN, Graham DM, Garcia-Corbacho J, Lopez J, Dutcus C, Okpara CE, Ghori R, Jin F, Groisberg R, Korakis I. Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple-negative breast cancer: Results from the triple-negative breast cancer cohort of the phase 2 LEAP-005 Study. Cancer. 2024 Oct 1;130(19):3278-3288. doi: 10.1002/cncr.35387. Epub 2024 Jun 21. PubMed 39031824 ↗
  • Ponz-Sarvise M, Rha SY, Gomez-Roca CA, Ortega Moran L, Gill S, Tortora G, Geva R, Saada-Bouzid E, Santoro A, Kim TW, Heudobler D, Dutcus CE, Okpara CE, Ghori R, Zhang Y, Vajdi A, Dettman EJ, Jin F, Groisberg R, Shapira-Frommer R. Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results from the Phase II LEAP-005 Study. Cancer Res Commun. 2026 Mar 1;6(3):673-686. doi: 10.1158/2767-9764.CRC-26-0018. PubMed 41747221 ↗
  • Victoria Ruiz I, Uboha NV, Jamal R, Mejia FC, Ahumada M, Im SA, Gomez-Roca C, Shapira-Frommer R, Perets R, Yanez E, Dutcus C, Okpara CE, Ghori R, Jin F, Groisberg R, Castanon E. Lenvatinib Plus Pembrolizumab for Patients With Previously Treated Advanced Colorectal Cancer: Results From the Phase II LEAP-005 Study. Clin Colorectal Cancer. 2026 Jun;25(2):225-238.e2. doi: 10.1016/j.clcc.2026.01.003. Epub 2026 Jan 22. PubMed 41763955 ↗
  • Rha SY, Castanon E, Gill S, Senellart H, Lopez J, Marquez-Rodas I, Victoria I, Kim TM, Lwin Z, Burger MC, Simonelli M, Cassier PA, Hendifar AE, Ascierto PA, Dutcus C, Okpara CE, Ghori R, Jin F, Groisberg R, Villanueva L. Lenvatinib plus pembrolizumab for patients with previously treated select solid tumors: Results from the phase 2 LEAP-005 study recurrent glioblastoma cohort. Cancer. 2025 Aug 15;131(16):e70015. doi: 10.1002/cncr.70015. PubMed 40808295 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2019 to primary completion in Oct 2024, 68 months.

Results were first posted in Nov 2025, 1 year after primary completion.

Of 255 phase 2 interventional studies under Triple Negative Breast Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 94. This study's 68 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2019
First posted
Jan 9, 2019
StartActual
Feb 12, 2019
Primary completionActual
Oct 28, 2024
CompletionActual
Oct 28, 2024
Results first posted
Nov 17, 2025
Last update
May 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03797326
Collaborators
Eisai Inc.
Responsible party
Sponsor
First posted
Jan 9, 2019
Start date
Feb 12, 2019
Primary completion
Oct 28, 2024
Completion
Oct 28, 2024
Results posted
Nov 17, 2025
Last update
May 4, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pembrolizumab · Lenvatinib

Start the discussion